Jan 25 (Reuters) - European Medicines Agency:
* EMA PUBLISHED CLINICAL DATA SUPPORTING EXTENSION OF INDICATION FOR SPIKEVAX TO INCLUDE USE IN ADOLESCENTS AGED 12 TO 17. Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.
Sign up for our Newsletter|Member Login
BRIEF-EMA Says Clinical Data Published Supporting Extension Of Indication For Spikevax To Include Use In Adolescents Aged 12-17
Newsletter sign up:
Trending
- Vanuatu breaks ground with 'loss and damage' costing in new climate plan
- As California sizzles, Amazon drivers feel the heat over metrics
- As seas rise, U.S. coastal landowners urged to let the water in
- Lebanese band Mashrou' Leila to split after online harassment
- What will new British PM Liz Truss do on LGBTQ+ issues?
Copyright © 2020 Thomson Reuters Foundation. Thomson Reuters Foundation is a charity registered in England and Wales (registration number: 1082139)
